Figure 5
Figure 5. CTI-inhibited fresh blood activated with rTf or LPS-THP-1 in the presence EA.hy926. Tubes containing a unilaminar layer of EA.hy926 with rTf (○) or LPS-THP-1 (▵) activated whole blood were used to measure (A) TAT formation, (B) prothrombin consumption, (C) FPA production, and (D) fVa generation (left), inactivation (right), and representative Western blot. FVa1-506 HC cleavage is shown but not quantified. Clot times in all experiments are indicated (▵ = 2.3 ± 0.10 minutes and ○ = 2.9 ± 0.14 minutes). Dashed line in a and c represents 95% confidence limits.

CTI-inhibited fresh blood activated with rTf or LPS-THP-1 in the presence EA.hy926. Tubes containing a unilaminar layer of EA.hy926 with rTf (○) or LPS-THP-1 (▵) activated whole blood were used to measure (A) TAT formation, (B) prothrombin consumption, (C) FPA production, and (D) fVa generation (left), inactivation (right), and representative Western blot. FVa1-506 HC cleavage is shown but not quantified. Clot times in all experiments are indicated (▵ = 2.3 ± 0.10 minutes and ○ = 2.9 ± 0.14 minutes). Dashed line in a and c represents 95% confidence limits.

Close Modal

or Create an Account

Close Modal
Close Modal